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Poster Session I S279Invasive mold infections (IMI) have been associated with signifi-
cant infectious relatedmortality post AlloSCT (Mehta et al ASBMT,
2010). We have previously demonstrated the safety and efficacy of
prophylactic liposomal amphotericin B (AMB) for 100 days post
AlloSCT in pediatric recipients (Roman/Cairo et al PBC, 2008).
Although AMB is effective for prophylaxis against IMI post Al-
loSCT, its association with nephrotoxicity and infusion related reac-
tions results in its discontinuation in. 10% of patients. Micafungin,
an echinocandin has been shown to be efficacious against both
Candida spp and Aspergillus spp with minimum toxicity and is
now approved for use as prophylaxis against invasive fungal infec-
tions in patients undergoing AlloSCT. (Pappas et al, 2009).
Methods: We conducted a prospective trial of administering pro-
phylactic AMB (3mg/kg/day) IV from d 0-44 then transitioning to
Micafungin (1mg/kg/day) IV at d 45 until d 100 if \ grade II
AGVHD at d +45. AGVHDprophylaxis were tacrolimus and myco-
phenolate mofetil (n 5 34) as we have previously described (Bhatia/
Cairo et al BBMT, 2009). Those who received CD-34 selected
PBSC (T-depleted) received tacrolimus only (n 5 15). Treatment
success was defined as prevention of IMI prior to day +100 post
AlloSCT.
Result: Median age: 8 yrs (2mo-23yr) Sex:14F, 35M Diagnose-
s:7ALL, 9AML, 6NHL, 1NBL, 6SAA, 1beta-Thal, 1MDS, 9SCD,
1FA, 1ALD, 2SCID, 1PNH, 1Atypical Wolmans, 3HLH. There
were 17CB donors (15-unrelated, 2-related), 16PBSC (15-unrelated,
1-related), 13RBM and 3URBM. The probability of developing $
grade II acute GVHD and extensive chronic GVHD was 12.2%
and 6%, respectively. There were no documented IMI within 100
days post transplantation. There were 7 documented invasive can-
dida infections (ICI). 4 ICI occurred while on AMB prior to switch-
ing to Micafungin, (mean of 21 days post AlloSCT), all infections
resolved in this cohort, the other 2 ICI occurred after switching to
Micafungin (mean of 30 days after switching) with one death due
to ICI. There were no reported side effects attributable to Micafun-
gin or discontinuation due to toxicity.
Conclusion: AlloSCT recipients are at high risk for both ICI and
IMI. Our preliminary data suggests that prophylaxis of AMB (D
0-44) and Micafungin (D 45-100) during the first 100 days post
AlloSCT is both safe and efficacious in preventing IMI. Larger ran-
domized studies are still needed to compare this combination to
other standard antifungal prophylaxis regimens.345
THE USE OF INTRAVENOUS ANTIBIOTICS AT THE ONSET OF NEUTROPE-
NIA IN PATIENTS RECEIVING HEMATOPOIETIC STEM CELL TRANS-
PLANTS: A ‘‘PRE-EMPTIVE’’ STRATEGY
Hamadah, A.1, Schreiber, Y.2, Toye, B.2, Doucette, S.3, McDiarmid, S.1,
Huebsch, L.1, Tay, J.1 1The Ottawa Hospital Blood and Marrow Pro-
gramme, Ottawa, ON, Canada; 2The Ottawa Hospital, Ottawa, ON,
Canada; 3Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background: Hematopoietic Stem Cell Transplant (HSCT) recip-
ients are at risk for fatal bacterial infections during the engraftment
period. Empirical antibiotic(s) at the onset of febrile neutropenia re-
main the standard of care. HSCT recipients began receiving intrave-
nous once daily ceftriaxone at the onset of neutropenia (neutrophils
\1.0) regardless of fever as part of The Ottawa Hospital Blood and
Marrow Outpatient Programme policy from Jan 2009; ‘‘pre-
emptive’’ approach. We examined the impact of this policy on
HSCT recipient outcomes.
Methods: A retrospective ‘‘before-after’’ study was conducted to
compare 2 cohorts [Jan 2008 - Dec 2008 (Empiric strategy) vs. Jan
2009 - Dec 2009 (Pre-emptive strategy)] of patients receiving
HSCT. Baseline characteristics between the groups were compared
with 2 sample tests. Categorical variables and continuous variables
were compared using Chi-squared and Wilcoxan rank-sum tests
respectively.
Results:There were 238 HSCTs performed between Jan 2008 and
Dec 2009 with 127 and 111 in the earlier and later cohorts respec-
tively. Baseline characteristics between the cohorts were similar.
Infection related mortality at 100 days after HSCT and during
the engraftment period were similar with a pre-emptive strategy
compared to an empiric strategy (7.2% vs 10.2%; p 5 0.41 and3.6% vs 7.1%; p 5 0.24) respectively. Further, there were no dif-
ferences in ICU admissions or length of hospital stay. Both micro-
biologically (MDI) and clinically documented infections (CDI)
were reduced (11.7% vs 29.1%;p 5 0.001 and 18.2% vs33.9%;p
5 0.007) with the pre-emptive strategy compared with an empiric
strategy. Importantly, recipients of autologous HSCT appear to
have a lower infection related mortality and reduced infection
related ICU admissions during the engraftment period with the
pre-emptive strategy compared to an empiric strategy (0% vs
6.8%; p 5 0.03 and 2.9% vs 12.2% p 5 0.04). The need for esca-
lation of antimicrobial treatments, resistance pattern of MDIs and
cost of antimicrobial treatment were not different between the two
groups.
Conclusions: The use of once daily intravenous ceftriaxone at the
onset of neutropenia in patients receiving HSCT is safe and effec-
tive particularly in patients receiving autologous HSCT. Further
studies are warranted to study the impact of this ‘‘pre-emptive’’
strategy.346
THE USE OF PSYCHOTROPIC MEDICATIONS IN PEDIATRIC STEM CELL
TRANSPLANT PATIENTS
Whitley, K.E.,Williams, T.,Muriel, A.C., Lehmann, L.E.,Duncan,C.N.
1Dana-Farber Cancer Institute, Boston, MA
The use of psychotropic medications during and following pedi-
atric hematopoietic stem cell transplant (HSCT) is not well de-
scribed. We performed a retrospective review of the prescription
of psychotropic medications during a two year period at our
institution. We report the use of the following medications from
admission to one year post-HSCT: fluoxetine, sertraline, fluvox-
amine, citalopram, trazodone, clonazepam, methylphenidate,
ziprazodone, apiprazole, risperidone, mirtazepine, bupropion,
escitalopram, olanzepine, and paroxetine. During this period 130
patients had a total of 152 transplants. Seventeen patients
(13.1%) were prescribed at least one of the medications investi-
gated. The majority of patients (55.6%) were prescribed more
than one medication. The medications used included: citalopram
(55.6%), risperidone (27.8%), methylphenidate (27.8%), clonaze-
pam (27.8%), trazodone (22.2%), mirtazepine (11.1%), escitalo-
pram (5.6%), and bupropion (5.6%). The timing of the initial
prescription of a psychotropic medication was prior to admission
(47.1%), during the initial transplant admission (29.4%), and 3-6
months post-HSCT (23.5%). Anxiety was the most common indi-
cation for starting a medication (30.3%) followed by depression
(18.2%), sleep disturbance (15.2%), mood stabilization (12.1%), fa-
tigue (9%), and other indication (15.2%). The median duration of
medication use was 116.4 days (range 3-374 days). Medications
were discontinued prior to one year post-HSCT due to symptom
improvement (38.5%), toxicity (7.7%), or patient refusal (11.5%).
34.6% were still on drug at one year post-HSCT and 7.7% died
prior to one year while receiving psychotropic medication. The
median age of patients who received psychotropic medications
was 13.5 years (4-19.6 years) compared to 7.4 years (0.5-22 years)
(p\ 0.0001) in patient who did not receive medications. There was
no significant difference in the sex, type of transplant, underlying
diagnosis, or presence of graft-versus-host disease between the
groups. Psychotropic medications are commonly prescribed in
this group of pediatric HSCT patients particularly in adolescents
and young adults. Further investigation is needed into the psychi-
atric needs of this high-risk population.347
USE OF PROCALCITONIN MEASUREMENTS TO DIAGNOSE INFECTION
IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
PATIENTS WITH FEVER
Kohashi, S., Nawa, Y., Matsubara, E., Nakase, K., Hara, M. Ehime
Prefectural Central Hospital, Matsuyama, Ehime, Japan
Background: Increase of CRP, WBC, and inflammatory cytokines
suggest the presence of inflammation but do not necessarily indicate
S280 Poster Session Iinfection. Procalcitonin (PCT) is a novel marker that reflects the se-
verity of infection. Allogeneic Hematopoietic Stem Cell Transplan-
tation (Allo-HSCT) patients often have febrile episodes, but it is not
easy to conclude that the fever is caused by infection. In this study, we
assessed the diagnostic usefulness of PCT for allo-HSCT patients
with fever.
Patients andMethods:We retrospectively analyzed among the 41
patients who underwent allo-HSCT at our hospital between Janu-
ary 2008 and July 2010, 17 patients with fever above 37.5C and
for whom PCT was measured (total of 28 febrile episodes). The
number of cases of underlying hematologic diseases were as fol-
lows: 11 acute myeloid leukemia, 2 myelodysplastic syndrome, 1
myeloproliferative disease, 6 acute lymphoid leukemia, 4 malignant
lymphoma, 2 aplastic anemia, 1 multiple myeloma, and 1 other dis-
ease. Fifteen and thirteen febrile events were from patients who
had myeloablative and non-myeloablative conditioning regimens,
respectively.
Results: We documented infection in 16/28 febrile episodes (13
bacterial infections, 2 fungal infections, and 1 viral infection), while
12 febrile episodes were not related to infection (10 acute GVHD, 1
drug, and 1 not specified). To determine whether the presence of
infection can be predicted by PCT, we divided the 41 patients
into two groups, one with neutrophil counts\ 100/ml (N\ 100
group) and the other with $ 100/ml (N $ 100 group). In the N
\ 100 group, the sensitivity, specificity, likelihood ratio, positive
predictive value, and negative predictive value were 42.8%, 75%,
1.7, 90.9%, and 27.2%, respectively; in the N $ 100 group, these
values were 50%, 75%, 2.0, 33.3%, and 85.7%, respectively. Dur-
ing neutropenia, positive PCT tended to show the presence of in-
fection. However, when the neutrophil count gradually increased,
fever with positive PCT tended to have non-infectious factors,
such as allograft immunoreactions. These results suggest that the
cause of fever could not be predicted by PCT alone when the neu-
trophils reach a certain level. However, the probability of a false
negative prediction of infection by PCT tended to decrease with
the increase of neutrophil count. Further analysis will be needed
with inflammatory markers and clinical signs together with PCT
in a prospective study to determine the utilization of PCT for
allo-HSCT patients.348
CARING FOR THE CAREGIVER IN THE STEM CELL TRANSPLANTATION
SETTING
Brown, S.L. The University of Texas M.D. Anderson Cancer Center,
Houston, TX
Caring for a sick person, especially one with cancer can be
a long term, overwhelming responsibility. Caring for these patients
often requires support across the continuum, to address physical,
psychosocial, spiritual, and emotional well-being. Expectations in-
clude, managing an increasingly complicated healthcare system, re-
maining optimistic, and taking care of personal needs, usually
without support for themselves. This is especially true in stem
cell transplantation settings where patient hospitalizations can
last for several weeks and daily outpatient clinic visits for several
months. Unaddressed caregiver needs present risks to physical
and mental health, which in turn may affect the care provided
for loved ones.
To address this concern, Caregiver’s Week was implemented on
a stem cell transplantation unit. This event was designed to address
caregiver stress by using techniques such as relaxation, diversion,
support, meeting spiritual needs, and providing an opportunity to re-
spond to concerns and questions of caregivers. Program components
include Bingo, Tea/TLC, crafts, relaxation, and holiday themed
events. Nursing staff is present to address questions, concerns, and
listen to caregivers discuss their experiences. A chaplain is available
to provide spiritual support as appropriate. This collaborative ap-
proach allows caregivers to receive support, as well as support one
another.
The response to Caregiver’s Week is overwhelmingly positive.
Participants report feeling rejuvenated, relaxed, and in better spirits.
In addition, they report making friends who are going through the
same experience and whom they feel understand their feelings;many of these friendships continue long-term, after patients are dis-
charged.
Supporting caregivers is essential in stem cell transplantation to
decrease stress, increase morale, and create support. By providing
a week of activities focused on caregivers, staff acknowledges the es-
sential role they play in promoting positive patient care and out-
comes. Future plans include continuation of the Caregiver Week
activities, incorporating additional supportive measures, as well as
creating new innovative events, while continuing to monitor prog-
ress and meet caregiver needs.349
SUPPORTING BONE MARROW TRANSPLANT CAREGIVERS: NURSING’S
INFLUENCE ON INCORPORATING CAREGIVER SUPPORT SERVICES INTO
THE DESIGN OF A NEW BONE MARROW TRANSPLANT UNIT
Spruill, A.D., Eron, B.W. University of North Carolina Healthcare,
Chapel Hill, NC
During the planning stages of the new North Carolina Cancer
Hospital (NCCH), nursing was solicited for their design input.
The BoneMarrowTransplant Unit (BMTU) staff nurses at theUni-
versity of North Carolina Healthcare recognized the opportunity to
address some stressors that transplant caregivers may face. Nursing
staff used this opportunity to incorporate caregiver support services
into the design of the new, larger facility. In an effort to decrease
transplant caregiver burden, several amenities for caregivers were
created.
In response to caregiver needs, a caregiver suite was created on
the unit. Within this area, a laundry room with a full sized washer
and dryer was incorporated. Also located within this area are two
separate sleep rooms. Each of these rooms contain two beds as
well as a television, sofa, and radio for patients’ caregivers; allow-
ing them to rest outside of the patient’s room without having to
leave the hospital. A shower facility is also located within this
same area.
A nourishment room was designed for caregivers’ convenience.
This room contains a full sized refrigerator, microwave, coffee ma-
chine, and cabinet space assigned to them for storage. Additionally,
the Comprehensive Cancer Support Program within the NCCH of-
fers caregivers breakfast every Friday morning as well as Tuesday
night dinner.
The unit’s waiting room functions as a meeting space for care-
givers. There is a computer, printer, and a microwave for their use.
This area hosts a weekly caregiver support group session lead by
the BMTU social worker and recreational therapist. A bulletin board
is also posted in this area to keep transplant caregivers abreast of sup-
port services available to them.
Nursing was highly influential in the implementation of these sup-
port amenities that has served to address and decrease some of the
daily stressors that some transplant caregivers experience.350
THE EFFECT OF DONOR CYTOMEGALOVIRUS (CMV) SEROLOGIC STATUS
ON OUTCOME AND SURVIVAL IN PATIENTS UNDERGOING ALLOGENIC
STEM CELL TRANSPLANTATION IN THE ERA OF CMV-PREEMPTIVE THER-
APY
Koh, L.P.1, Tay, P.F.1, Poon, M.L.M.1, Hwang, W.Y.K.2, Loh, Y.S.M.2,
Tan, L.K.1, Goh, Y.T.2, Tan, B.1, Lee, J.J.2, Zhang, X.H.2, Lee, Y.M.1,
Ng, H.Y.1, Linn, Y.C.1 1National University Health System, Singapore;
2Singapore General Hospital, Singapore
Background: Cytomegalovirus continues to be a common cause of
morbidity and mortality after allogenic hematopoietic stem cell
transplantation (SCT) despite major advances in diagnostic tech-
niques and antiviral prophylactic strategies. Recipient CMV-sero-
positivity is a major predictor of adverse outcomes. Data regarding
the effect of the donor serologic status on seropositive recipient out-
comes remains controversial, with some studies reporting a beneficial
effect of seropositive donor, either reduction in relapse or reduction
in nonrelapse mortality (NRM), whereas other studies have found no
benefit from seropositive donor.
